Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
Figlin
Robert A
RA
Department of Urology, School of Medicine, UCLA, Los Angeles, CA 90095, USA. rfiglin@med1.medsch.ucla.edu
Alvin
H
H
Meinhardt
C L
CL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000235:genetics; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics; D014612:Vaccines / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014612:Vaccines; D042461:Vascular Endothelial Growth Factor A; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases; C497446:VHL protein, human